MLTX — MoonLake Immunotherapeutics

Summary of MLTX Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• No specific financial metrics or results were disclosed during the call, focusing instead on clinical trial outcomes and strategic direction.

2. Strategic Updates and Business Highlights

• The VELA program, comprising VELA-1 and VELA-2 trials, evaluated sonelokimab for moderate to severe hidradenitis suppurativa (HS).
• VELA-1 met all primary and secondary endpoints with a statistically significant delta of 17% for HiSCR75 compared to placebo.
• VELA-2 faced challenges due to a higher-than-expected placebo response, resulting in a borderline p-value of 0.053 for the primary endpoint.
• The company maintains that the trials have merit and will continue to seek regulatory advice to clarify the path forward.
• Sonelokimab demonstrated strong responses in pain scores and quality of life metrics, which are critical for patient care.

3. Forward Guidance and Outlook

• Management is optimistic about the regulatory path for sonelokimab, believing it has a strong chance of approval despite the challenges faced in VELA-2.
• The company plans to engage with regulatory authorities within the next one to three months to discuss the trial results and potential approval pathways.
• MLTX is also advancing other indications for sonelokimab, including palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA).

4. Bad News, Challenges, or Points of Concern

• The unexpected high placebo response in VELA-2 raised concerns about the validity of the trial results, leading to a need for further investigation.
• The company acknowledged that the results did not meet market expectations, which could impact investor sentiment and stock performance.
• There is uncertainty about the regulatory feedback and what additional data or trials may be required to support approval.

5. Notable Q&A Insights

• The management team, including Jorge da Silva and Kristian Reich, emphasized that they do not view the VELA-2 trial as a failure and are committed to exploring all avenues for regulatory approval.
• Professor Alexa Kimball highlighted the inherent variability in HS studies and the challenges of assessing treatment efficacy, suggesting that continued treatment often leads to improved outcomes.
• The company has a strong cash position of $425 million and operates with a low cash burn, allowing for prudent capital management despite the recent challenges.
• There was a discussion about the competitive landscape, with management expressing confidence in sonelokimab's ability to compete effectively against existing therapies, citing its high efficacy and favorable safety profile.

Overall, while the call highlighted significant challenges related to the VELA-2 trial results, management remains optimistic about the future of sonelokimab and its potential impact on HS treatment.